Inventiva confirms NATiV3 completion; on track for Q4 2026 topline

What happened

Inventiva announced that the last patient has completed the 72-week visit in the Phase III NATiV3 trial, and the company remains on track to report top-line results in the fourth quarter of 2026. This milestone means that data collection for the primary endpoint timepoint is complete for all 1,009 randomized patients in the main cohort, a necessary step before unblinding and analysis. The update refines the prior guidance of 'second half 2026' to a specific quarter, consistent with earlier expectations. It materially reduces the operational risk that had been a key concern following the treatment-related SUSAR and protocol tightening, as the trial has now passed the full treatment duration without further reported interruptions. Attention now shifts entirely to the quality of the efficacy and safety data, as the binary readout will determine whether lanifibranor can compete in the evolving MASH market against Madrigal's Rezdiffra and Novo Nordisk's Wegovy.

Implication

Investors should view the completion of the 72-week treatment period as a positive operational milestone that reduces the probability of trial delays or integrity issues that had previously weighed on sentiment. With the primary endpoint data collection now finished, the remaining uncertainty is almost entirely clinical: whether lanifibranor achieves statistically significant improvements in MASH resolution without worsening fibrosis, and fibrosis improvement without worsening MASH, with a clean safety profile. The company's cash runway is expected to extend to mid-Q1 2027, which should be sufficient to reach the readout, but any unexpected additional financing needs before then could dilute shareholders. The competitive backdrop remains challenging, as Rezdiffra and Wegovy are already on the market, and lanifibranor will need to show clear differentiation to secure a meaningful share. Given the binary nature of the Q4 2026 topline, the risk/reward is inherently asymmetric; a positive outcome could lead to a substantial re-rating, while a negative outcome would likely cause a severe decline, so position sizing should reflect this uncertainty.

Thesis delta

The thesis is modestly strengthened by the confirmation that all patients have completed the 72-week treatment period, reducing the risk of trial conduct issues that were a concern after the prior SUSAR. The primary investment debate now narrows to data quality and efficacy/safety outcomes, with the topline expected in Q4 2026. The WAIT rating remains appropriate as the binary event approaches, but the attractive entry price of $5.50 may become more compelling if the stock pulls back on broader market weakness, given the reduced operational risk.